MedWatch

Novo CEO is on the hunt for future growth: "The pressure is bigger than ever"

Lars Fruergaard Jørgensen and the rest of Novo Nordisk are starting to plan for the future, when the firm's crucial patents have expired. This is a big task that requires a lot of effort, the CEO says.

At the turn of the year, Lars Fruergaard Jørgensen will have been the CEO of Novo Nordisk for the past five years. He took over the role on Jan. 1, 2017, after the firm's former long-standing CEO Lars Rebien Sørensen. "The five years have just flown by. Time has gone extreme fast," says Fruergaard Jørgensen. | Photo: Stine Bidstrup/ERH

The thought of executing another formidable decade with high growth and continued progress is a bit of a headache for the CEO of Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs